Abstract
Unleashing adaptive immunity via immune checkpoint inhibitors (ICPIs) in many cancer types led to durable antitumor responses and prolonged survivals and also added some new immune-related adverse events (irAEs) to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have